Free tool
FAERS Monitor: Riabni
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761140 or its brand name (Riabni, Rituximab-Arrx). Reports on generic versions are filed under their own applications.
Reports
384
Serious
63
16% of reports
Hospitalization
28
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product storage error165
- circumstance or information capable of leading to medication error116
- off label use64
- intercepted product administration error51
- fatigue19
- infusion related reaction18
- accidental exposure to product17
- drug ineffective16
- dyspnoea16
- intercepted product preparation error16
- malaise15
- pruritus15
- dizziness14
- drug intolerance14
- rash13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 8 |
| 2022 | 49 |
| 2023 | 121 |
| 2024 | 143 |
| 2025 | 39 |
| 2026 | 22 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,775 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| intercepted product administration errorSignal | 51 | 366.8 | 283.8 | 18,125 |
| circumstance or information capable of leading to medication errorSignal | 116 | 188.8 | 162.1 | 21,438 |
| product storage errorSignal | 165 | 103.4 | 92.2 | 16,673 |
| intercepted product preparation errorSignal | 16 | 71.3 | 44.1 | 1,039 |
| infusion related reactionSignal | 18 | 14.9 | 9.5 | 220 |
| accidental exposure to productSignal | 17 | 9.0 | 5.7 | 114 |
| drug intoleranceSignal | 14 | 7.9 | 4.7 | 78 |
| off label useSignal | 64 | 4.0 | 3.2 | 147 |
| pruritusSignal | 15 | 2.1 | 1.3 | 8 |
| malaise | 15 | 1.9 | 1.1 | 5 |
| rash | 13 | 1.6 | 1.0 | 3 |
| dyspnoea | 16 | 1.5 | 1.0 | 3 |
| dizziness | 14 | 1.5 | 0.9 | 2 |
| fatigue | 19 | 1.3 | 0.9 | 1 |
| drug ineffective | 16 | 0.7 | 0.4 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.